CLAIM AMENDMENTS

1. (currently amended)   A recombinant ~~Recombinant~~ antibody recognizing IOR C2 antigen, the recombinant antibody being produced ~~and single-chain Fv fragment derived~~ from murine monoclonal antibody IOR C5 produced by the hybridoma deposited with the European Collection of Cell Cultures under accession number ~~ECCC~~ 97061101, wherein said recombinant antibody comprises ~~has the~~ Complementary Determining Regions (CDRs) ~~CDRs~~ and framework regions (FRs) of the murine monoclonal antibody IOR C5 and humanized ~~human~~ constant regions in its ~~for~~ light and heavy chains, wherein the heavy and light chains comprise at least one framework region point mutation for reducing its immunogenicity.

2.-4. (cancelled)

5. (currently amended, previously once amended)   The recombinant ~~Humanised~~ antibody according to claim 1, wherein the framework region point mutation is selected from the group consisting of: ~~4 which has in the framework regions of the heavy and light chains any of the following point mutations~~

HEAVY CHAIN:

Position 10 ASP for GLY

Position 17 SER for THR

Position 43 ASN for LYS

4

Position 44 LYS for GLY

LIGHT CHAIN:

Position 15 ILE for LEU

Position 45 LYS for ARG

Position 63 THR for SER

6. (cancelled)

7. (currently amended)   Cellular line expressing the recombinant antibody of ~~any of~~

claims 1 or ~~to~~ 5.

8. (currently amended)   Host cell which expresses ~~express~~ the single chain Fv

fragment of claims <u>16 or 17</u> ~~1 and 6~~.

9. (currently amended)   Pharmaceutical composition for treating recto and colon

malignant <u>tumors</u> ~~tumours~~, metastasis thereof and recurrences, comprising the

recombinant antibody of ~~any of~~ claims 1 <u>or</u> ~~to~~ 5 and a suitable excipient.

10. (currently amended)   Pharmaceutical composition for treating recto and colon

malignant <u>tumors</u> ~~tumours~~, metastasis thereof and recurrences, comprising the single

chain Fv fragment of claims <u>16 or 17</u> ~~1 and 6~~ and a suitable excipient.

11. (currently amended)   Pharmaceutical composition for <u>localization</u> ~~localisation~~ and

identification "*in vivo*" of recto and colon malignant <u>tumors</u> ~~tumours~~, metastasis thereof

and recurrences, comprising the recombinant antibody of ~~any of~~ claims 1 <u>or</u> ~~to~~ 5.

12. (currently amended)   Pharmaceutical composition for <u>localization</u> ~~localisation~~ and

identification "*in vivo*" of recto and colon malignant <u>tumors</u> ~~tumours~~, metastasis thereof

and recurrences, comprising the single chain Fv fragment of claims <u>16 or 17</u> ~~1 and 6~~.

13. (currently amended)   Pharmaceutical composition according to claims 9 <u>or 11</u> ~~to~~

~~12~~ comprising also compounds for radiolabeling <u>the</u> ~~these~~ antibodies ~~o fragments,~~

~~which are mixed to produce an aqueous administrable solution~~.

14. (currently amended)   Pharmaceutical composition according to claim 13

comprising technetium ~~tecneciun~~ 99, rhenium ~~rhenio~~ 186, rhenium ~~rhenio~~ 188 or

analogues as <u>radiolabelers</u> ~~radiolabellers~~.

15. (cancelled)

16. (new)   A single chain Fv fragment recognizing IOR C2 antigen, the Fv fragment

being produced from murine monoclonal antibody IOR C5 produced by the hybridoma

deposited with the European Collection of Cell Cultures under accession number

97061101, said Fv fragment containing the Complementary Determining Regions

(CDRs) and frameworks regions (FRs) of the murine monoclonal antibody IOR C5 and

humanized constant regions in its heavy and light chains, wherein the heavy and light chains comprise at least one framework region point mutation for reducing its immunogenicity.

17. (new)   The single chain Fv fragment according to claim 16, wherein the framework region point mutation is selected from the group consisting of:

HEAVY CHAIN:

Position 10 ASP by GLY

Position 17 SER by THR

Position 43 ASN by LYS

Position 44 LYS by GLY

LIGHT CHAIN:

Position 15 ILE by LEU

Position 45 LYS by ARG

Position 63 THR by SER

18. (new)   Pharmaceutical composition according to claims 10 or 12 further comprising compounds for radiolabeling the Fv fragments.

19. (new)   Pharmaceutical composition according to claim 18 comprising technetium 99, rhenium 186, rhenium 188 or analogues as radiolabelers.